Abstract
Introduction
It is now clear that inflammation and cancer initiation and progression are linked. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine with described cancer stimulatory and also cancer inhibitory properties. The study’s aim was to assess the potential of circulating IL-6 as a prognostic indicator in colorectal cancer.
Materials and methods
A literature search was conducted using PubMed, restricted to articles published in English language. We compared published results in regard to differences in IL-6 levels between healthy controls and colon cancer patients (seven published results), between patients with increasing tumor stages (eight published results), between patients with differences in tumor size (four published results), and between patients with and without liver (three published results) or lung metastasis (one published result). Furthermore, we reviewed the literature in regard to the possible correlation of IL-6 levels with survival time (five published results) and correlation of IL-6 levels and lymph node involvement (three published results).
Results
Concerning colon tumors, results are consistent. Colon cancer patients reveal higher serum IL-6 levels than healthy controls. Furthermore, higher IL-6 levels are associated with increasing tumor stages and tumor size, with metastasis and decreased survival.
Conclusion
Therefore, circulating IL-6 might be prognostic indicator in colorectal cancer.
Similar content being viewed by others
Introduction: interleukin-6 signaling
Colorectal cancer represents a significant cause of morbidity and mortality worldwide. The molecular pathogenesis of colorectal cancer is still poorly understood. At least in some subtypes of colon cancer the immune system seems to have tumor-promoting activity. One approach to get deeper insight into the biology of colon cancer is the evaluation of circulating cytokines and cytokine receptors, which have received a great deal of attention as potential diagnostic and prognostic markers in cancer patients. One important cytokine in colon cancer is interleukin-6 (IL-6) with its pleiotropic properties. After IL-6 is secreted from the activated monocyte, macrophage, or tumor cell, it can act on target cells. IL-6 first binds to the membrane-bound IL-6 receptor (IL-6R; mainly expressed on hepatocytes, neutrophils, monocytes/macrophages, and some lymphocytes). This complex of IL-6 and IL-6R associates with the signal-transducing membrane protein gp130, inducing its dimerization and initiation of signaling (reviewed in [1], Fig. 1a). Besides the membrane-bound IL-6R, a naturally occurring soluble form of the IL-6R (sIL-6R) is generated by two independent mechanisms, limited proteolysis of the membrane protein, and translation from an alternatively spliced mRNA [2–4]. Interestingly, the sIL-6R together with IL-6 stimulates cells that only express gp130 [5–7], a process named transsignaling (Fig. 1b).
Dimerization of gp130 is followed by the rapid activation of tyrosine kinases of the Janus Kinase (Jak) family for initial signal transduction [1]. Jak activation leads to activation of downstream signaling pathways, including phosphatidylinositol 3′-kinase, and mitogen-activated protein kinases. An important target of gp130 signaling is the oncogene STAT3 [8–10]. STAT3 is a member of the STAT family of latent cytoplasmic transcription factors. After gp130 activation, STAT3 becomes tyrosine phosphorylated, homo- or heterodimerizes, and translocates to the nucleus where it induces gene transcription. STAT3 transcriptionally activates numerous important cellular genes involved in growth regulation, differentiation, and cell cycle, including c-myc and bcl-2 [8].
Interleukin-6 effects on colorectal cancer cells
IL-6 seems to have significant effects on colon cancer cells. IL-6 has been demonstrated to promote the growth of colon cancer cells in vitro [11]. Moreover, IL-6 has been implicated to promote cancer growth, because it has been shown to enhance colony formation of human colon carcinoma cells in vitro in a dose-dependent manner [11]. IL-6 increases invasiveness of colon cancer cells [12] and likely promotes secondary tumor formation through its angiogenic potency. Brozek et al. [13, 14] could show that IL-6 level is low in normal human mucosa and rises only moderately during progression from adenomatous to low grade (G1 and G2) cancer lesions. High levels of IL-6 were observed in rather undifferentiated lesions (G3–G4). These results imply that IL-6 can accelerate tumor progression towards malignancy.
Previous animal studies demonstrated a functional relationship between transforming growth factor (TGF)-ß signaling in tumor-infiltrating cells and IL-6 transsignaling in colon carcinogenesis. It could be shown that TGF-ß production in tumor-infiltrating T lymphocytes suppresses tumor growth in the colon via inhibition of IL-6 production and subsequent IL-6 signal transduction. IL-6 signal transduction was mediated by the soluble rather than the membrane bound IL-6R. Furthermore, it was shown that IL-6 transsignaling is essential for colon carcinogenesis in mice lacking the TGF-ß receptor II and can induce phosphorylation of STAT3 and cell cycle progression in dysplastic epithelial cells [15, 16].
Results
IL-6 levels in colorectal cancer patients and healthy controls
Concerning the significance of IL-6 in colorectal cancer patients, published results in PubMed are relatively consistent (Table 1). We found seven different studies comparing serum IL-6 levels in colon cancer patients with levels of healthy subjects, e.g., the investigation of Galizia et al. (2002) [17]. The authors found IL-6 levels to be more elevated in cancer patients (n = 50, 9.3 ± 2.1 pg/ml; median, 8.8) than in the 25 healthy subjects (4.4 ± 0.8 pg/ml; median, 4.2). In addition to the elevated IL-6 level, they found a relationship between IL-6, tumor status, and presence of distant metastases. Furthermore, they compared preoperative IL-6 level of surgically cured patients with level of patients subjected to noncurative resection and found the latter to be significantly higher (10.8 ± 2.2, n = 20) than that of the curative patients (8.3 ± 1.0, n = 30). Similar results were shown by Dymicka-Piekarska et al. (2007) [18]. They measured IL-6 levels in 42 colorectal cancer patients and 38 healthy volunteers and found out that IL-6 levels were significantly increased in patients (stages I and II (n = 24), 2.98 ± 1.49 pg/ml; stage III (n = 18), 4.15 ± 2.45 pg/ml) as compared with the control group (1.31 ± 0.55 pg/ml). Significantly elevated IL-6 levels in patients are also found by studies of Kinoshita et al. (70 patients, 35.7 ± 69.0 pg/ml vs. 34 healthy volunteers, 4.3 ± 1.0 pg/ml) [19], Chung and Chang (164 patients, median value 11.89 pg/ml vs 20 healthy volunteers, median value 3.41 pg/ml) [20] and Ueda et al. (24 patients, 5.96 ± 1.89 pg/ml vs 64 healthy subjects, <3.1 pg/ml) [21]. Nikiteas et al. [22] found elevated median IL-6 levels (n = 74, 8.11 pg/ml) in colorectal cancer patients compared with normal individuals (3.52 pg/ml) in a Greek population. Kaminska et al. [23] analyzed the levels of different cytokines, among them IL-6, in 50 healthy volunteers and 157 patients with previously untreated colorectal cancer. The median IL-6 level of the patients (2.8 pg/ml) was significantly higher than those of the healthy persons (0.8 pg/ml).
Interleukin-6 levels and different tumor stages
The idea that high serum IL-6 is associated with colorectal carcinoma is supported by further studies analyzing IL-6 and different tumor stages. In Table 1, the results are summarized according to the number of analyzed patients in each study. Comparing different stages of colorectal cancer, Esfandi et al. [24] found a significant association between increasing serum IL-6 levels and staging of the tumor (stage I, 2.75 ± 0.2 pg/ml, n = 11; stage II, 4.14 ± 0.51 pg/ml, n = 8; stage III, 5.86 ± 1.68 pg/ml, n = 23; stage IV, 9.56 ± 0.99 pg/ml, n = 8). The authors conclude that serum IL-6 level may reflect the proliferative activity of the tumor in patients with colorectal carcinoma. Similar results were found by Belluco et al. [25]. The study of Kaminska et al. [23] analyzed the levels of different cytokines, among them, IL-6 in 50 healthy volunteers and 157 patients with previously untreated colorectal cancer. IL-6 increased with tumor stage (I, 1.7; II, 3.2; III, 2.8; IV, 4.9 pg/ml; all median values) and also with infiltration of the colon wall. These data support their preliminary studies on pre- and postoperative serum cytokine levels, e.g., IL-6, in colorectal carcinoma patients [26]. Similar data were found by Chung and Chang [20]. The proportion of patients with IL-6 levels ≥12 pg/ml increased in a Dukes’ stage-related manner. Their data confirm those previously reported by Ueda et al. [21] on a group of 24 patients with colorectal carcinoma showing significantly higher concentrations of IL-6 in Dukes’ D patients (n = 8, 12.16 ± 4.99 pg/ml) compared with those in Dukes’ A–C patients (n = 16, 2.86 ± 0.71 pg/ml).
Three other studies did not find a close connection between increasing tumor stages and increasing IL-6 concentrations, two medium-sized studies [19, 22] and a small-sized study [18] (Table 1). Although the study of Nikiteas et al. [22] did not find a significant association of IL-6 and tumor stages, the authors found positively correlating results for higher serum IL-6 levels in patients compared with healthy controls, an association of higher IL-6 levels with increasing tumor size and even for higher IL-6 levels and decreased survival. Kinoshita et al. [19] found similar results. They did not find a significant association of high IL-6 and different stages, but IL-6 levels showed a trend to higher levels in stage IV tumors (I, 31.5 ± 76.2; II, 23.2 ± 40.0; III, 22.7 ± 20.2; IV, 62.0 ± 115.2 pg/ml). Furthermore, they found correlating results for higher IL-6 levels in colon cancer patients compared with controls, and an association of higher IL-6 levels and increasing tumor size. Furthermore, patients with liver metastasis had higher IL-6 levels than patients without liver metastasis. No significant association of high IL-6 levels and increasing tumor stages was also found by the relatively small-sized study of Dymicka-Piekarska et al. [18], but also a trend could be seen to higher levels and increasing stages (I/II, 2.98 ± 1.49; III, 4.15 ± 2.45 pg/ml). Furthermore, they found positively correlating results for higher serum IL-6 levels in patients compared with controls.
In summary, Table 1 shows that the three largest studies reveal an association of high serum concentration of IL-6 and increasing tumor staging. Results are supported by two medium-sized and one small-sized study. Three studies showing no association of IL-6 and tumor stages showed at least a trend in IL-6 levels and/or further positive correlations of other tumor features/clinical parameters like survival or tumor size. Therefore, we conclude that high serum concentration of IL-6 is significantly associated with high colon tumor stages.
Interleukin-6 levels and tumor size
We found four studies correlating IL-6 levels with tumor size. Ueda et al. [21] found out that serum IL-6 levels were significantly higher in patients (8.78 ± 3.25 pg/ml, n = 13) whose tumors exceeding 5 cm in diameter compared with IL-6 levels of patients with smaller tumors (2.64 ± 0.96 pg/ml, n = 11). These results are supported by the study of Kinoshita et al. [19]. The authors could show that serum concentration of IL-6 correlated significantly with tumor size. Similar results were shown by Chung and Chang [20]. The maximal size of the tumor in the high (≥12 pg/ml) IL-6 group (5.29 ± 0.27 cm, n = 81) was significantly larger than that in the low IL-6 group (4.43 ± 0.19 cm, n = 83). The fourth study done by Nikiteas et al. [22] used 8 pg/ml as threshold level. Again, the maximum size of the tumor in the high IL-6 group (≥8 pg/ml, 4.8 ± 1.9 cm, n = 35) was significantly larger than that in the low IL-6 group (3.8 ± 1.3 cm, n = 39).
Interleukin-6 levels and metastasis
Three groups found significantly increased IL-6 levels in patients with liver metastasis (76.3 ± 127.3, 34.15 ± 59.51 and 12.24 ± 5.77 pg/ml, respectively) compared with patients without liver metastases (23.2 ± 32.6, 10.77 ± 23.24 and 3.38 ± 0.84 pg/ml, respectively) [19–21]. One study compared IL-6 levels of patients with (n = 4) and without (n = 20) lung metastasis and found IL-6 levels of patients with lung involvement to reveal higher IL-6 levels (20.55 ± 7.92 pg/ml) than patients without lung metastasis (3.05 ± 0.73 pg/ml) [21].
Interleukin-6 levels and survival
Chung and Chang [20] analyzed the association of serum IL-6 and survival. They could show that survival of colorectal cancer patients correlated with serum IL-6 levels in a concentration-related manner. Patients with IL-6 ≥ 12 pg/ml were more often found to have advanced disease. Therefore, the authors conclude that IL-6 levels might be used as a tumor marker for monitoring the treatment course of colorectal cancer. We found four further reports analyzing the association of IL-6 and survival (Table 1). The study of Belluco et al. [25] showed that a preoperative IL-6 serum concentration of more than 10 pg/ml was a negative prognostic factor of survival. Patients with an IL-6 serum concentration of more than 10 pg/ml (n = 78) had a significantly shorter 5-year survival than patients with an IL-6 serum concentration of 10 pg/ml or less (n = 120). Similar results were published by Rich et al. [27] analyzing 80 patients with metastatic colorectal cancer. Patients with serum IL-6 level below the overall median IL-6 value had a median survival of 15.7 months, whereas a median survival of 8.8 months was found in those patients with serum IL-6 concentration above median value. Patients with high IL-6 had significantly poorer survival rate at 2 years regardless of their performance status, as estimated by Kaplan-Meier. Nikiteas et al. [22] found that patients with increased serum IL-6 concentrations (≥8 pg/ml) showed a decrease in overall survival. However, the study of Galizia et al. [17], analyzing 30 patients could not show a difference in disease-free survival between high and low IL-6 levels. Although the authors found elevated IL-6 levels in colon cancer patients compared with control and an association of increasing IL-6 and increasing tumor stages and presence of distant metastases, they did not find a difference in disease-free survival between high and low IL-6 levels.
In Table 1, results are summarized according to patients’ numbers. Two large studies with more than 100 patients found a significant association of IL-6 and survival [20, 25]. Also, two medium-sized studies showed the same results [22, 27]. The study of Galizia et al. [17] showed no correlation of IL-6 and survival. This study is a comparatively small study. One should take into consideration that only 30 patients were evaluated for IL-6 and survival. Results might be different when analyzing a larger number of patients. Therefore, we conclude that a high IL-6 level is a negative prognosticator in colon cancer in regard to survival.
Interleukin-6 levels and lymph node involvement
Concerning different aspects of the colon tumor biology like tumor stages, tumor size, involvement of liver and/or lung metastases, and patients’ survival, the overwhelming majority of studies shows a significant correlation of high IL-6 levels and colon cancer. Concerning lymph node involvement situation seems to be contradictory. The study of Chung and Chang [20] found higher IL-6 levels in patients with lymph node metastasis (n = 85, 21.44 ± 45.51 pg/ml) compared with patients without lymph node involvement (n = 79, 7.80 ± 19.09 pg/ml). Contrary to this study are the results of Nikiteas et al. [22] and Kinoshita et al. [19]. IL-6 levels of patients with and without lymph node involvement were not significantly different. Therefore, the correlation of IL-6 levels and lymph node metastasis is not clear and needs further investigation.
Discussion
In analogy to breast tumors [28], serum levels of IL-6 are increased in colon cancer patients and correlate with prognosis. The mechanism by which serum IL-6 raises is not known. One explanation might be the G/C polymorphism at position −174 in the IL-6 gene promoter region. Previously, it could be shown that the −174C allele is less efficiently translated into protein than its −174G counterpart [29]. Hefler et al. [30], analyzing ovarian cancers, found that at an early tumor stage ovarian cancer cells expressed predominantly −174C alleles, whereas at later stages the −174G polymorphism prevailed. In accordance with these results and in regard to colon cancer, Belluco et al. [31] found that colon cancer patients carrying the −174G polymorphic IL-6 gene had significantly higher IL-6 serum levels than patients with the −174C genotype. The authors conclude that this genetic variant might be a prognostic molecular marker, and it should be investigated additionally in prospective studies.
Another possible explanation for the cancer-associated IL-6 elevation might be gene amplification. In a recent publication, Tchirkov et al. [32] evaluated IL-6 gene amplification in tumors from 53 glioma patients using fluorescence in situ hybridization (FISH approach). No IL-6 gene amplification was detected in low-grade or anaplastic tumors, whereas high-level amplification was found in 15 out of 36 glioblastomas (GBM). Furthermore, GBM patients with amplified IL-6 gene had significantly shorter survival than patients without amplification. Multiple Cox analysis for overall survival, including IL-6 amplification, extent of tumor resection, and age as variables, demonstrated that IL-6 amplification was an independent factor of poor prognosis. The authors conclude that amplification of the IL-6 gene leading to its overexpression is likely one of the major factors contributing to the aggressiveness and poor response to therapies of GBM.
Summary and conclusion
The summary of published results in regard to IL-6 levels in colorectal carcinoma patients and different tumor features/clinical parameters shows that high serum concentrations of IL-6 are associated with tumor progression, metastasis and poor survival. Based on the present data of the literature search, we conclude that circulating IL-6 might be a prognostic indicator in colorectal cancer. The cytokine IL-6 emerges as at least a companion of colon cancer pathogenesis. Furthermore, these results let us speculate that IL-6 might act as a tumor-promoting cytokine in colon cancer or it might be (among others) a key player. IL-6 might even represent a therapeutic target, at least in some subtypes of colon cancer which are connected to inflammation-related causes.
References
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(1):1–20 Review
Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96–100
Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11:613–624
Althoff K, Mullberg J, Aasland D, Voltz N, Kallen K, Grotzinger J, Rose-John S (2001) Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J 353(Pt 3):663–672
Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581
Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027
Rose-John S, Schooltink H (2007) Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 174:57–66
Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548–2556
Schindler CW (2002) Series introduction. JAK-STAT signaling in human disease. J Clin Invest 109:1133–1137
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295–303
Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H (2000) Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151:31–38
Hsu CP, Chung YC (2006) Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res 26:4607–4614
Brozek W, Bises G, Girsch T, Cross HS, Kaiser HE, Peterlik M (2005) Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 41:2347–2354
Brozek W, Bises G, Fabjani G, Cross HS, Peterlik M (2008) Clone-specific expression, transcriptional regulation, and action of interleukin-6 in human colon carcinoma cells. BMC Cancer 8:13
Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501
Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178
Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, Kemona-Chetnik I, Kemona H (2007) Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 20:585–590
Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85:2526–2531
Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226
Ueda T, Shimada E, Urakawa T (1994) Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29:423–429
Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G (2005) Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639–1643
Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, Chechlinska M (2005) Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor. Tumour Biol 26:186–194
Esfandi F, Mohammadzadeh Ghobadloo S, Basati G (2006) Interleukin-6 level in patients with colorectal cancer. Cancer Lett 244:76–78
Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133–138
Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M (2000) CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 6:38–41
Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Levi F (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757–1764
Knupfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102:129–135
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376
Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB (2003) An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63:3066–3068
Belluco C, Olivieri F, Bonafè M, Giovagnetti S, Mammano E, Scalerta R, Ambrosi A, Franceschi C, Nitti D, Lise M (2003) 174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9:2173–2176
Tchirkov A, Khalil T, Chautard E, Mokhtari K, Véronèse L, Irthum B, Vago P, Kémény JL, Verrelle P (2007) Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96:474–476
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knüpfer, H., Preiss, R. Serum interleukin-6 levels in colorectal cancer patients—a summary of published results. Int J Colorectal Dis 25, 135–140 (2010). https://doi.org/10.1007/s00384-009-0818-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-009-0818-8